227 results on '"Nowakowski G"'
Search Results
2. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials
3. Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells
4. P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS
5. P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS
6. PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
7. P1094: CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS WITH T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AT A LARGE TERTIARY CARE CENTER
8. PB2073: LACK OF AGREEMENT ON EVENT-FREE SURVIVAL DEFINITION IN MARGINAL ZONE LYMPHOMA
9. P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
10. P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
11. P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY
12. PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
13. PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
14. PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA IN THE MAGNIFY PHASE 3B INTERIM ANALYSIS OF INDUCTION R2 FOLLOWED BY MAINTENANCE
15. SUBGROUP ANALYSES OF ELDERLY PATIENTS AGED 70 YEARS IN MAGNIFY: A PHASE 3B INTERIM ANALYSIS OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
16. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages
17. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
18. CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study.
19. Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL).
20. Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes.
21. AN OPEN‐LABEL TRIAL OF ORAL CA‐4948 AN IRAK4 INHIBITOR COMBINED WITH IBRUTINIB IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
22. THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)
23. BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (TRIAL IN PROGRESS)
24. INTERIM PET/CT PREDICTS OUTCOMES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH FRONTLINE LENALIDOMIDE/RCHOP (R2CHOP): LONG‐TERM ANALYSIS OF MC078E
25. INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY
26. PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31)
27. INDUCTION R 2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY
28. FIRST‐MIND: A PHASE IB, OPEN‐LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL
29. IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
30. ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)
31. DO CELL‐OF‐ORIGIN, DOUBLE EXPRESSER, AND DOUBLE HIT STATUS AFFECT OUTCOMES IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (R/R DLBCL)? A PROSPECTIVE OBSERVATIONAL STUDY
32. PROGRESSION‐FREE SURVIVAL AT 24 MONTHS AS A LANDMARK AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
33. Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma
34. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
35. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma
36. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma
37. Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets
38. INTERIM ANALYSIS OF MAGNIFY PHASE IIIB: INDUCTION R2 FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL)
39. Bowel perforation in intestinal lymphoma: incidence and clinical features
40. Performance optimization of two-bed closed-cycle solid-sorption heat pump systems
41. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia
42. Effect of operating conditions on the performance of two-bed closed-cycle solid-sorption heat pump systems
43. SAFETY AND EFFICACY OF THE PD-L1 INHIBITOR DURVALUMAB WITH R-CHOP OR R2 -CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH-RISK DLBCL
44. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2 ) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS
45. PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)
46. PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA
47. PRE-TREATMENT HEMOGLOBIN AND OUTCOME IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ANTHRACYCLINE CONTAINING CHEMOTHERAPY
48. PS1249 EXTRANODAL AND SPLEEN DISEASE DETECTED BY FDG-PET/CT IS ASSOCIATED WITH EARLY CLINICAL FAILURE IN UNTREATED FOLLICULAR LYMPHOMA
49. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2 ) VS RITUXIMAB/PLACEBO (AUGMENT)
50. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2 ) THAN RITUXIMAB/PLACEBO
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.